Durable Responses to Atezolizumab Plus Bevacizumab in HCC
Saadvik Raghuramy shared a post on X about a recent paper by Ying-Chun Shen et al. published in JCO.
Authors: Ying-Chun Shen, Tsung-Hao Liu, Alan Nicholas, Masatoshi Kudo, Ann-Lii Cheng et al.
“HCC Patients achieving a durable response with ATEZO/BEV i.e. a PR or SD tend to have much more favourable outcome.
- mOS not estimatable for patients with durable PR
- mOS 23.7 months for durable SD
- pCR more frequent with PR (57%).”
Source: Saadvik Raghuramy/X
Saadvik Raghuramy is the Head of the Department of Medical Oncology at Arete Hospitals. Dr. Saadvik specializes in treating a wide range of cancers, including breast, stomach, colorectal, liver, esophageal, prostate, kidney, bladder, oral, brain tumors, and lung cancers.
His clinical expertise includes immunotherapy, monoclonal antibody therapy, chemotherapy, cancer screening, palliative care, targeted therapy, clinical trials, cancer genetic counseling, and hormone therapy.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023